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Abstract 
Betulin derivatives have been proven effective in vitro against Leishmania donovani amastigotes, which cause visceral 
leishmaniasis. Identifying the molecular targets and molecular mechanisms underlying their action is a currently an 
unmet challenge. In the present study, we tackle this problem using computational methods to establish properties 
essential for activity as well as to screen betulin derivatives against potential targets. Recursive partitioning classifica-
tion methods were explored to develop predictive models for 58 diverse betulin derivatives inhibitors of L. donovani 
amastigotes. The established models were validated on a testing set, showing excellent performance. Molecular 
fingerprints FCFP_6 and ALogP were extracted as the physicochemical properties most extensively involved in 
separating inhibitors from non-inhibitors. The potential targets of betulin derivatives inhibitors were predicted by 
in silico target fishing using structure-based pharmacophore searching and compound-pharmacophore-target-
pathway network analysis, first on PDB and then among L. donovani homologs using a PSI-BLAST search. The essen-
tial identified proteins are all related to protein kinase family. Previous research already suggested members of the 
cyclin-dependent kinase family and MAP kinases as Leishmania potential drug targets. The PSI-BLAST search suggests 
two L. donovani proteins to be especially attractive as putative betulin target, heat shock protein 83 and membrane 
transporter D1.
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Background
Leishmaniasis is a neglected tropical disease caused by 
Leishmania protozoan parasites that affect millions of 
people worldwide [1–3]. During the past decade, leish-
maniasis has spread considerably, and an increasing 
number of new cases are being reported every year [3]. 
Several treatments exist for leishmaniasis [4], but they 
are not fully active, have adverse effects, loss of efficacy 
and are highly expensive [5]. Hence, there is an urgent 
need to develop new, safe and effective medications.
Betulin derivatives have a significant in vitro inhibition 
growth of L. donovani amastigotes, which cause visceral 
leishmaniasis, the most severe form of the disease [6, 7]. 
Betulinic acid and other betulin derivatives have further-
more remarkable antiviral [8–11], anti-HIV [12], antiul-
cer [13], anti-inflammatory [14, 15], anti-malaria [16, 17] 
and anti-tumoral [18–20] activity that make this class of 
compounds promising for new drugs discovery [21–24]. 
Structure–activity relationships and pharmacological 
properties of betulin have been studied previously [25–
29]. Recently, our collaborators have synthesized 58 betu-
lin heterocyclic derivatives and evaluated their activity 
and selectivity against L. donovani amastigotes with simi-
lar or better inhibitory activity (> 80%) than some well-
known antibiotics (Nystatin, Pentamycin, Amphotericin) 
[6, 30, 31]. Computational methods such as QSAR [32] 
and pharmacophore modeling [33] are important meth-
ods in modern drug discovery that have been successfully 
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applied for modeling activities of betulin derivatives 
[34–42]. However, the congeneric series are still limited, 
and the mechanism of action of these compounds are still 
undefined. To date, very few computational studies and 
models have been done on Betulin derivatives to explore 
the full potential of this class of compounds, with one 
derivatives in clinical phase 3 (Oleogel-S10), and accel-
erate the understanding of their mode of action. In the 
present study, we report an application of classification 
method, recursive partitioning (RP) to build predictive 
models of the inhibitory activity of betulin derivatives 
and characterize their molecular properties. RP models 
can select essential molecular descriptors according to 
the decrease of the performance resulting from the ran-
dom permutation of the variables. Also, we investigated 
the compound-target interaction network and poten-
tial pharmacological actions by reverse pharmacophore 
database screening. Although it can be to some extent 
debated [43], it is commonly accepted that structur-
ally similar compounds have similar biological activity 
[44] and may also recognize homologous targets across 
organisms [45]. This concept spurs us to assume the 
proteins interacting with compounds that are similar to 
betulin derivatives in the structure are potential binding 
targets as well. We thus screened potent betulin inhibi-
tors of Leishmania growth against PharmaDB [46], a 
database containing a collection of pharmacophores 




The molecular structures and biological data used in this 
study, 58 betulin derivatives synthesized by the Yli-Kau-
haluoma group, were retrieved from references [6, 30, 
31] (Table 1). The biological activities are reported as the 
percentage inhibition of L. donovani axenic amastigotes 
growth at 50  μM concentrations. Three datasets were 
generated, and the compounds were categorized in dif-
ferent classes depending on their % of inhibition (%I) in 
three different ways (Table 2). Dataset 1, the compounds 
were divided into two classes as active (%I ≥ 49) and inac-
tive (%I < 49). Dataset 2, the compounds were divided 
into three classes as active (%I > 69), moderate active 
(%I ≥ 36 et ≤ 69) and inactive (%I < 36). Dataset 3, is simi-
lar to Dataset 2 but the group of moderately active com-
pounds, considered as an uncertainty buffer, is not used. 
Generating the molecular structures and conformational 
analysis
The skeleton of betulin derivatives was drawn using 
ChemBioDraw Ultra 12.0, assigning hydrogen atoms with 
Maestro 9.6 (Schrödinger). After that, the dataset was 
prepared by Discovery Studio 4.5 (Accelrys Inc.) (DS 4.5). 
Partial charges of structures were calculated based on the 
CHARMm force field. Full minimization was run with 
the Smart minimizer algorithm until root mean square 
gradient was 0.01 and maximum 2000 steps. No implicit 
solvent model was included.
Recursive partitioning (RP) models
RP is a classification method for multivariable data anal-
ysis. It creates a decision tree to correctly classify and 
uncover relationships between members of the dataset 
based on a dichotomous splitting of a dependent prop-
erty, in our case compounds properties and their %I. RP 
analysis was carried out using DS 4.5 to develop deci-
sion trees that categorize the compounds into two and 
three classes based on the % inhibition. RP single tree 
(ST) models and multi-tree bagged forest (BF) models 
made up of multiple trees were used. Both ST and BF 
models are particularly appropriate in case of imbal-
anced training data and are easily interpretable, while 
also providing a significant degree of predictive accu-
racy [47–50]. For both methods, a training set was used 
to build the decision trees, and a test set was utilized to 
evaluate the predictive power of the models. Using two 
splitting methods, we generated two training and test 
sets from each of the three datasets (see Tables  3 and 
4). The first method (split by diversity) assigns a diverse 
subset of compounds to the training and test set. The 
second way (random per cluster) cluster the compounds 
by similarity and then randomly assigned compounds 
from each group between the training and test set. Both 
methods use 2D fingerprint molecular descriptors and 
a proportion of 70% data for the training versus 30% for 
the test set.
BF has a relatively small number of trees (10) generated 
using a separate bootstrap sample of the original data for 
each tree. All descriptors are considered as possible split-
ting criteria for each node and weighting method is set to 
“by class” by default, to compensate for imbalanced data. 
All others parameters were set to default. BF can measure 
how each descriptor contributes to the prediction accuracy 
in the course of training. We estimated the predictive abil-
ity of the ST models with five fold cross-validation and BF 
models using out-of bag statistics. For BF, in each bootstrap 
training set, around one-third of the instances are left out, 
constituting the out-of-bag sample. The test set was used 
to estimate the fitting ability of the ST and RF models on 
a new dataset that was not used in the model construction. 
The performance of the ST and BF models are based on 
three metrics: true positive rate (recall or sensitivity), speci-
ficity, and the area under the curve (AUC) of the receiver 
operating characteristics (ROC) plot. AUC or ROC score 
represents the probability that a classifier will be estimated 
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Table 1 Experimental Leishmanial growth inhibitory activities of betulin derivatives against L. donovani axenic amastigotes
1 OH CH2OH CH3-C=CH2 35 3.56
2 OH CH3-C=CH2 8.8 2.17
3 OH CH3-C=CH2 10.5 2.35
4 OH CH3-C=CH2 13.4 2.60
5 OH CH3-C=CH2 16.6 2.81
6 OH CH3-C=CH2 59.2 4.08
7 OH CH3-C=CH2 86 4.45
8 OAc OH CH3-C=CH2 37.4 3.62
9 OH CHO CH3-C=CH2 64.3 4.16
10 OH CO2H CH3-C=CH2 50.5 3.92
11 O= CH2OAc CH3-C=CH2 40.6 3.70
12 O= CHO CH3-C=CH2 46.2 3.83
13 O= CO2H CH3-C=CH2 98.1 4.59
14 O= CO2H CH3CHCH3 72.1 4.28
15 O= CO2Me CH3-C=CH2 40.1 3.69
16 O= CH3-C=CH2 69.3 4.24
17 H CH2OH CH3-C=CH2 13.2 2.58
18 OH CH=NOH CH3-C=CH2 69.1 4.24
19 =NOH CH=NOH CH3-C=CH2 72.1 4.28
20 OAc CN CH3-C=CH2 62.7 4.14
21 CO2H CH3-C=CH2 100.4 4.61
 
Compound R1 R2 R3 Inhibition 
(%) at 50 
µm  
pI50exp 
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Table 1 (continued)
22 CO2H CH3-C=CH2 23.4 3.15
23 CO2H CH3-C=CH2 29.3 3.38
24 CO2H CH3-C=CH2 92.7 4.53
25 CH3-C=CH2 94.9 4.55
26 CO2H CH3-C=CH2 87.9 4.48
27 CO2H CH3-C=CH2 95.7 4.56
28 CO2H CH3-C=CH2 60.2 4.10
29 CH3-C=CH2 84.3 4.43
30 CH3CHCH3 2.4 0.88
31 CH2OH CH3-C=CH2 56.9 4.04
32 CH3-C=CH2 6.1 1.81
33 CH3-C=CH2 34.2 3.53
34 =NOH CH3-C=CH2 2.8 1.02
35 
 
CO2H CH3-C=CH2 98.2 4.59 
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correctly, with values 0.5 indicating better than random 
prediction and 1 signifying perfect prediction [51].
Target fishing
By screening a compound against a panel of pharmaco-
phore models derived from multiple pharmacological 
targets, the potential targets of the compound can be out-
lined. Automated ligand profiling available in DS 4.5 so-
called “Ligand Profiler” protocol was used [52]. DS 4.5 is 
equipped with a pharmacophore database PharmaDB that 
is the largest ever-reported collection of structure-based 
pharmacophores, 68,056 entries from 8166 protein-ligand 
X-ray structures [46, 53, 54]. These pharmacophores are 
derived from the sc-PDB dataset, a collection of 3D struc-
tures of binding sites found in the Protein Data Bank. 
For most actives betulin derivatives, all the pharmaco-
phore models from PharmaDB were selected for the vir-
tual screening with default settings. The rigid mode was 
used as the molecular mapping algorithm. No molecular 
features were allowed to be missed while mapping these 
compounds to the pharmacophore models to increase 
selectivity. The minimal inter-feature distance was set at 
Table 1 (continued)
52 98 4.58
53 H 88 4.48







49 H 48 3.87
50 49 3.89
51 88 4.48
Table 2 Dataset used for recursive partitioning classification models
Class 1 (inactive) Class 2 (moderate active) Class 3 (active) Total
Dataset 1 Activity < 49 Activity ≥ 49
31 0 27 58
Dataset 2 Activity < 36 36 ≥ Activity ≤ 69 Activity > 69
22 19 17 58
Dataset 3 Activity < 36 36 ≥ Activity ≤ 69 Activity > 69
22 Excluded 17 39
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0.5 Å. For each target, the name and pathway information 
was collected from ChEMBL [55] and WikiPathways [56] 
databases using KNIME [57] version 3.1.2. Compound-
Target-Pathway networks were generated by Cytoscape 
3.0 (Cytoscape Consortium, USA) [58] where network 
nodes illustrate compounds, targets, and biological path-
ways. The edges linking the compound-target and target-
pathway describe their relationships. Position-Specific 
Iterated BLAST (PSI-BLAST) search is done to identify 
the homologous protein in L. donovani from the selected 
target as the query sequence [59].
Results
Structural diversity analysis, RP (ST/BF) model 
development and interpretation
The robustness and efficiency of classification models 
are usually affected by the diversity of dataset used for 
modeling, with the effect that the more diverse are the 
compounds, the broader will be the applicability of the 
model. The dissimilarity between any two molecules was 
computed using a Tanimoto coefficient. In this study, the 
average fingerprint distance for the dataset of 58 betulin 
derivatives inhibitors is 0.7 with a minimum of 0.12 and 
maximum at 0.9. Figure 1a shows a broad range of diver-
sity across compounds. Also, the data set has an average 
molecular property distance of 1.33, minimum at 0.067 
and maximum at 2.75 which shows good structural and 
property diversity of the dataset. Two different methods, 
diversity and random per cluster were used to split the 
dataset into test and training sets. (see Tables  3 and 4) 
Different inhibitory classes with varying distributions of 
training-test where thus created (Fig. 1b).
Detailed result of ST and BF models are reported 
Tables 3 and 4 respectively. The ST and RF models per-
formance are comparable. As shown, BF was able to 
find predictive models from dataset 2 with both split-
ting method. The ROC score for the in-bag training data 
for all trees in the forest model is 0.99 and 0.96, and the 
out-of-bag ROC score is 0.59 and 0.71 for the training 
set. The in-bag results are predictions for the data used 
to train the tree, while the out-of-bag results are predic-
tions for the left-out data. The external test sets including 
13 and 10 compounds respectively were used to evaluate 
the predictive ability of the two models. The ROC score 
on external test sets is good, 0.87 and 0.94 respectively. 
The confusion matrix, as well as sensitivity and specific-
ity values, are presented in Additional file  1: Table  S1, 
Additional file  2: Table  S2. In the betulin derivatives 
inhibitors models, RF and ST method can correctly clas-
sify most of the molecules of the external test set. These 
outcomes indicate that the developed ST and RF models 
show favorable and robust prediction performance. The 
Y-randomization test was performed four times, and the 
AUC values for the model using the data set with experi-
mental activity values were significantly higher than 
those obtained from the dataset with randomized values, 
indicating the robustness of our models. The most suit-
able sets of molecular descriptors for predicting Betulin 
derivatives inhibitors were extracted from the RF predic-
tion models via feature selection. A summary of descrip-
tors based on their frequency of occurrences in the 
models are given in Table 5. The FCFP_6 feature, number 
aromatic rings, number rings, molecular fractional polar 
surface area, molecular weight, number rotatable bonds 
are predominant in all models. In general, the frequency 
at which a descriptor was selected empirically appears 
to distinguish truly important descriptors from others 
best. In the RF models of betulin derivatives inhibitors, 
FCFP_6 feature, number aromatic rings are the most crit-
ical descriptors for classification.
Profiling results
The profiling results from 13 most actives compounds are 
presented in Table 6. The fit value was used to measure 
the fitness of the ligand and pharmacophore. A fit value 
equal or higher to 0.9 was used as a threshold to select 
targets from the activity profiler result (see Fig.  2). The 
13 compounds mapped 47 pharmacophores models out 
of a total of 68,056 models with a rigid mapping and the 
presence of all molecular features required. These mod-
els belonged to 32 protein targets and were involved in 
184 pathways. Protein sequences of all the predicted tar-
gets were collected, and a blast search was run on NCBI 
server to identify homolog in L. donovani (Table 7).
Pharmacological network analysis
A topological analysis of the network pharmacology 
compound-pharmacophore-target-pathway offered 
insights into the biologically relevant connectivity pat-
terns, and profoundly essential targets or pathways. A 
general overview of the global topological properties of 
the network was obtained from the statistical data by the 
Network Analyzer of Cytoscape. The full pharmacologi-
cal network of L. donovani betulin derivatives inhibitors 
had three types of nodes, compounds, pharmacophores, 
and targets with related pathway information (Addi-
tional file  3: Fig. S1). The 13 compounds nodes formed 
the core of the network which fit 47 pharmacophores 
and was surrounded by the target nodes. Each target 
was linked to at least one pathway. A total of 209 path-
way nodes constituted the outer layer of the network. 
Most pharmacophores were the center of a sub network-
shaped connection. For seven targets, no pathway was 
identified. Three pharmacophores are involved in a little 
number of pathways, between 2 and 3 for each proposed 
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target. Six pharmacophores formed a closed network of 
2–4 pathways for each target. Pharmacophores, targets, 
and pathways were strongly interconnected in many-
to-many relationships. Figure  3 presents a subset of the 
pharmacological network of L. donovani betulin deriva-
tives inhibitors limited to its most connected compounds 
and targets nodes. The diameter of the network was 10, 
the centralization was 0.18, and the density was 0.011. 
To reduce the number of candidate targets and identify 
more potential targets based on targets identified from 
network pharmacology, the degrees distribution of all 
the alkaloids (Fig. 4a) and essential targets (Fig. 4b) were 
investigated. The compounds with higher degree val-
ues (≥ 9), such as 1, 3, 4, 5, 6, 7 and 8, that participate 
in more interactions than the other components are the 
hubs in the network. The target degree values ranged 
between 1 and 50. The targets with the highest degree 
(≥ 10) values are MAP kinase p38 alpha (50), Glycogen 
synthase kinase-3 beta (36), Cyclin-dependent kinase 2 
(29), Tyrosine-protein kinase JAK2 (27), Heat shock pro-
tein HSP 90-alpha (23), PI3-kinase p110-gamma subunit 
(17), Tyrosine-protein kinase LCK (14), Tyrosine-pro-
tein kinase 2 beta (12), Serine/threonine-protein kinase 
Chk1(11) and 14-3-3 protein sigma (10). The highly 
Table 3 Bagged forest models
Splitting method Training Test
Dataset ROC score Dataset ROC score






0.97 0.72 1 (11)
2 (6)
0.73
R C 1 (25)
2 (17)




(2 Class from 3)
Diversity 1 (13)
2 (13)
0.99 0.59 1 (9)
2 (4)
0.87
R C 1 (20)
2 (9)












R C 1 (20)
2 (13)
3 (9)




Table 4 Simple tree models
Training Test







0.89 0.62 1 (11)
2 (6)
0.71
R C 1 (25)
2 (17)




(2 Class from 3)
Diverse 1 (13)
2 (13)
0.91 0.63 1 (9)
2 (4)
0.80
R C 1 (20)
3 (9)












R C 1 (20)
2 (13)
3 (9)
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connected nodes are referred to as the hubs of the net-
work for target prediction. To find the relations between 
target proteins and the critical pathway further, we ana-
lyzed the target-pathway network. Logically, the weight 
of one pathway which contains many druggable target 
proteins is more significant than for many pathways 
including a single target protein that can be actioned 
by many drug molecules. The critical pathways (highest 
degree level) are summarized in Fig.  4c. These results 
suggested that B Cell Receptor Signaling, Brain-derived 
neurotrophic factor (BDNF) signaling, Integrated Pan-
creatic Cancer, Oncostatin M Signaling pathways may 
bind compounds with pharmacophoric similarities to 
betulin derivatives. Homologous targets were identified 
in L. donovani from the PSI-BLAST search as the poten-
tial target of Betulin derivatives. Table  7 shows a sum-
mary of L. donovani homologous targets with E-value < 3. 
A total of 27 proteins selected as similar to one or more 
targets identified by target fishing.
Discussion
It is well known that the unknown targets and under-
lying mechanisms restrict the development of novel 
therapeutics against Leishmania. In silico predic-
tive modeling offer new tools to overcome these 
shortages. However, many existing methodologies 
offers complex predictive models and relative appli-
cability by the experimental chemist. To increase 
the utility, we proposed classification models and 
compounds-target-pathway interaction network to pre-
dict Leishmania activity of new compounds and dis-
cern the targets and potential pathways from a set of 
betulin derivatives active in  vitro against L. Donovani. 
We successfully build two type of recursive partition-
ing classification models, single tree and bagged forest 
models. A forest model is less directly interpretable 
than a single-tree model in that there is not merely 
one tree to interpret, but depending on the type of for-
est, anywhere from tens to hundreds of trees. On the 
other hand, a forest model provides statistical measures 
of the relative importance of the various descriptors 
in distinguishing among the different classes, which 
Fig. 1 a Compounds similarity distance (Tanimoto score). b Distribution of compounds in % inhibition classes for the three datasets
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Table 6 Targets selected by the target pharmacophore screening with fit value > 0.9
ID Uniprot ID Gene name Title Family
3ac3 P06239 LCK_HUMAN Tyrosine-protein kinase Lck Protein kinase
3ad4 P06239 LCK_HUMAN Tyrosine-protein kinase Lck Protein kinase
3mzs P00189 CP11A_BOVIN Cholesterol side-chain cleavage enzyme, mitochondrial Cytochrome P450
3my0 P37023 ACVL1_HUMAN Serine/threonine-protein kinase receptor R3 Protein kinase
1lox P12530 LOX15_RABIT Arachidonate 15-lipoxygenase Lipoxygenase
1qyx P14061 DHB1_HUMAN Estradiol 17-beta-dehydrogenase 1 Short chain dehydrogenases/reductases (SDR)
2bik P11309 PIM1_HUMAN Serine/threonine-protein kinase pim-1 Protein kinase
2br1 O14757 CHK1_HUMAN Serine/threonine-protein kinase Chk1 Protein kinase
2chw P48736 PK3CG_HUMAN Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic 
subunit gamma isoform
PI3/PI4 kinase
2chz P48736 PK3CG_HUMAN Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic 
subunit gamma isoform
PI3/PI4 kinase
2p0m P12530 LOX15_RABIT Arachidonate 15-lipoxygenase Lipoxygenase
2wxq Q3UDT3 Q3UDT3_MOUSE Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic 
subunit delta isoform
PI3/PI4 kinase
3ddu P48147 PPCE_HUMAN Prolyl endopeptidase Peptidase S9A
3h3c Q14289 FAK2_HUMAN Protein-tyrosine kinase 2-beta Protein kinase
3hrb Q16539 MK14_HUMAN Mitogen-activated protein kinase 14 Protein kinase
3le6 P24941 CDK2_HUMAN Cyclin-dependent kinase 2 Protein kinase
3mqe Q05769 PGH2_MOUSE Prostaglandin G/H synthase 2 Prostaglandin G/H synthase
3p2v P15121 ALDR_HUMAN Aldose reductase Aldo/keto reductase
3r7r P48736 PK3CG_HUMAN Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic 
subunit gamma isoform
PI3/PI4 kinase
3rgz O22476 BRI1_ARATH Protein brassinosteroid insensitive 1 Protein kinase
3s3g P15121 ALDR_HUMAN Aldose reductase Aldo/keto reductase
3tfq P28845 DHI1_HUMAN Corticosteroid 11-beta-dehydrogenase isozyme 1 Short chain dehydrogenases/reductases (SDR)
3ugr P42330 AK1C3_HUMAN Aldo-keto reductase family 1 member C3 Aldo/keto reductase
3zrl P49841 GSK3B_HUMAN Glycogen synthase kinase-3 beta Protein kinase
4a79 P27338 AOFB_HUMAN Amine oxidase [flavin-containing] B Flavin monoamine oxidase
2hpy P02699 OPSD_BOVIN Rhodopsin G-protein coupled receptor 1
3gql P11362 FGFR1_HUMAN Fibroblast growth factor receptor 1 Protein kinase
2ab2 P08235 MCR_HUMAN Mineralocorticoid receptor Nuclear hormone receptor
3lmp P37231 PPARG_HUMAN Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor
1pzo P62593 BLAT_ECOLX Beta-lactamase TEM Class-A beta-lactamase
1zhx P35844 KES1_YEAST Oxysterol-binding protein homolog 4 Oxysterol-binding protein
1zhz P35844 KES1_YEAST Oxysterol-binding protein homolog 4 Oxysterol-binding protein
2oxd P28523 CSK2A_MAIZE Casein kinase II subunit alpha Protein kinase
2x00 Q8WSF8 Q8WSF8_APLCA Soluble acetylcholine receptor Neurotransmitter-gated ion-channel
3hgy Q7B8P6 Q7B8P6_CAMJU cmeR Transcriptional regulator
3ov4 P00947 SDIS_COMTE Steroid delta-isomerase Steroid delta-5-4-isomerase
3s92 Q15059 BRD3_HUMAN Bromodomain-containing protein 3 Bromodomain and extraterminal domain
3smo P31947 1433S_HUMAN 14-3-3 protein sigma 14-3-3 protein
4a01 O22124 O22124_VIGRA Pyrophosphate-energized vacuolar membrane proton pump H(+)-translocating pyrophosphatase (TC 3.A.10)
4a86 P15494 BEV1A_BETPN Major pollen allergen Bet v 1-A Bet v I type allergen
4a8v P43183 BEV1J_BETPN Major pollen allergen Bet v 1-J Bet v I type allergen
2iws P02829 HSP82_YEAST ATP-dependent molecular chaperone HSP82 Heat shock protein Hsp90
3b27 P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha Heat shock protein Hsp90
2xa4 O60674 JAK2_HUMAN Tyrosine-protein kinase JAK2 Protein kinase
4a9n P25440 BRD2_HUMAN Bromodomain-containing protein 2 Bromodomain and extraterminal domain
4alh P25440 BRD2_HUMAN Bromodomain-containing protein 2 Bromodomain and extraterminal domain
3svg O60885 BRD4_HUMAN Bromodomain-containing protein 4 Bromodomain and extraterminal domain
Page 11 of 16Zhang et al. J Cheminform  (2018) 10:40 
Fig. 2 Compounds that fit each pharmacophore with shape fit value > 0.9
Table 7 Leishmania donovani homologous targets from PSIBLAST search wit evalue < 3
Uniprot ID Gene name Title %Identity Evalue Bit score Query
P27890 HSP83_LEIDO Heat shock protein 83 61.76 0 568 P07900|HS90A_HUMAN
Q01440 GTR1_LEIDO Membrane transporter D1 34.83 0.004 30.8 P21616|AVP_VIGRR 
A4ZZ93 DHYSL_LEIDO Inactive deoxyhypusine synthase 19.70 0.042 26.2 P42330|AK1C3_HUMAN
P39050 TYTR_LEIDO Trypanothione reductase 64.71 0.051 27.7 P11362|FGFR1_HUMAN
E9BDA8 GMPR_LEIDB GMP reductase 25.64 0.073 25.4 P24941|CDK2_HUMAN
P43151 GPA_LEIDO Putative guanine nucleotide-binding protein subunit alpha 27.03 0.099 25.4 P49841|GSK3B_HUMAN
P17804 HSP70_LEIDO Heat shock 70 kDa protein 33.33 0.24 23.9 P62593|BLAT_ECOLX
P36889 SAHH_LEIDO Adenosylhomocysteinase 26.72 0.24 23.5 P28845|DHI1_HUMAN
A7LBL2 PURA_LEIDO Adenylosuccinate synthetase 27.66 0.27 25 Q15059|BRD3_HUMAN
Q27675 CYAA_LEIDO Receptor-type adenylate cyclase A 29.73 0.31 21.6 P00947|SDIS_COMTE
P23223 GP63_LEIDO Leishmanolysin 37.84 0.33 24.3 P37231|PPARG_HUMAN
Q25263 CYAB_LEIDO Receptor-type adenylate cyclase B 28.36 0.52 24.6 Q3UDT3|Q3UDT3_MOUSE
P21620 IMDH_LEIDO Inosine-5’-monophosphate dehydrogenase 47.37 0.57 22.7 P15121|ALDR_HUMAN
Q9BIC6 PFKA_LEIDO ATP-dependent 6-phosphofructokinase 28.95 0.59 22.7 P14061|DHB1_HUMAN
Q05889 LPG1_LEIDO Galactofuranosyl glycosyltransferase 28.07 0.69 24.6 O60885|BRD4_HUMAN
D9IFD5 DOHH_LEIDO Deoxyhypusine hydroxylase 38.46 0.71 23.1 P37023|ACVL1_HUMAN
Q01441 GTR2_LEIDO Membrane transporter D2 38.46 0.79 23.1 P27338|AOFB_HUMAN
P12522 ATXB_LEIDO Probable proton ATPase 1B 25.69 1.1 22.3 P35844|KES1_YEAST
P11718 ATXA_LEIDO Probable proton ATPase 1A 25.23 1.2 22.3 P35844|KES1_YEAST
O00874 DPOLA_LEIDO DNA polymerase alpha catalytic subunit 22.22 1.2 23.1 P48147|PPCE_HUMAN
P55905 COQ5_LEIDO 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, 
mitochondrial
41.18 1.5 22.3 P02829|HSP82_YEAST
Q05885 ARD1_LEIDO N-terminal acetyltransferase complex ARD1 subunit 
homolog
32.56 1.6 21.9 P02829|HSP82_YEAST
P12522 ATXB_LEIDO Probable proton ATPase 1B 50 1.8 21.6 P35844|KES1_YEAST
P27116 DCOR_LEIDO Ornithine decarboxylase 29.55 2.2 22.7 P48736|PK3CG_HUMAN
Q36736 KM11_LEIDO Kinetoplastid membrane protein 11 27.59 2.6 19.2 P31947|1433S_HUMAN
Q25264 DCAM_LEIDO S-adenosylmethionine decarboxylase proenzyme 42.11 2.7 21.6 Q15059|BRD3_HUMAN
B5APK2 DHYS_LEIDO Deoxyhypusine synthase 36.36 2.9 20.4 P28845|DHI1_HUMAN
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is not available with single-tree models. When none 
of the descriptors is strongly correlated with the class 
membership, single-tree models can be brittle, in that 
a relatively small change in the training data results in 
a significant difference in the structure of the tree, and 
thus in the tree’s predictions. A forest model helps to 
address this problem. In principle, Network analysis 
has the potential to allow the target identification of L. 
donovani betulin derivatives inhibitors. The proteins in 
the hubs of the network (highly connected nodes) are 
highly associated with each other. The most critical 
proteins with high degree value are all related to protein 
kinase family. Among them, MAP kinase p38 alpha, 
Glycogen synthase kinase-3 beta, Cyclin-dependent 
kinase 2, Tyrosine-protein kinase JAK2, Heat shock 
protein HSP 90-alpha, PI3-kinase p110-gamma subu-
nit, Tyrosine-protein kinase LCK, Protein tyrosine 
kinase 2 beta, Serine/threonine-protein kinase Chk 
and 14-3-3 protein sigma. They are involved in direct-
ing cellular responses to a diverse array of stimuli 
(such as mitogens, heat shock, and pro-inflammatory 
cytokines) and regulate proliferation, gene expres-
sion, mitosis, cell survival, apoptosis and many other 
cell functions [60]. The mode of action of these critical 
proteins may be done through the integrated biologi-
cal network rather than by individual target. The four 
central pathways, B Cell Receptor, Brain-derived neu-
rotrophic (BDNF), Integrated Pancreatic Cancer and 
Fig. 3 Subset of the pharmacological network of L. donovani Betulin derivatives inhibitors limited to the hubs of the network for target prediction. 
Betulin derivatives inhibitors, pharmacophore, and targets with a red to gray gradient scale
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Oncostatin M, have higher frequencies than the rest. 
Members of the cyclin-dependent kinase family and 
MAP kinases had been previously identified as essential 
for Leishmania and suggested as potential drug targets 
[61]. Homologous targets, Heat shock protein 83 and 
Membrane transporter D1 were identified as a possible 
target in L. donovani and proposed for experimental 
validation. Among the chaperones, heat shock protein 
83 (Hsp83) is alternately referred to as Hsp90 or Hsp86 
due to the variable molecular weight amongst different 
orthologues is a family of emerging targets for infec-
tious diseases. Hsp83 is best known as cancer targets 
with some drug candidates in clinical development [62, 
63]. Transporters are proteins that play a role in bring-
ing small molecules across biological membranes. The 
function of transporters as therapeutic targets is a well-
established new field of research [64]. Transporters are 
new therapeutic targets for treating rare diseases. But 
Fig. 4 Nodes degree distribution in the pharmacological Betulin derivatives inhibitors network. a Degree distribution of Betulin derivatives inhibitor 
nodes, b degree distribution of target nodes, c degree distribution of pathway nodes
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there is no, till today, a case of exploration of Hsp83 or 
Membrane transporter D1 as a drug target in L. dono-
vani. The results offer the opportunity to characterize 
the chemical sensitivity of the parasitic chaperone and 
Membrane transporter D1 against our library of Betu-
lin derivatives L. donovani inhibitors with biophysical 
and biochemical techniques.
Conclusion
In this study, Recursive partitioning (both ST and BF) 
methods were firstly used to develop classification mod-
els for the inhibitory activity of 58 betulin derivatives 
in  vitro against L. donovani amastigotes. These models 
can be used to screen a large compound library for facili-
tating the discovery of the novel lead compounds. Most 
relevant molecular features of betulin derivative inhibi-
tion were identified. These features provide an excellent 
analytical perspective to explain the similarities and dif-
ferences between betulin derivative inhibitors and non-
inhibitors. The potential targets of these compounds 
were determined through in silico target fishing, which 
combines 3D structure-based pharmacophore searching 
and network pharmacology analysis. Using this strategy, 
we inferred links between most active compounds and 
Leishmaniasis disease through molecular targets and 
keys signaling pathways. Further studies need to validate 
identified targets and to test the effects of betulin deriva-
tives on identified pathways and their interactions (Addi-
tional file 4: Fig. S2, Additional file 5).
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